-
Trump Threatens Heavy Taxes on US Firms Building Data Centers Abroad
-
Kuwait DGCA Delegation Attends ICAO Assembly in Montreal
-
Gozo Minister Clint Camilleri Appointed CPMR Vice-President for Maritime Affairs
-
Charlie Puth and Ellie Goulding to Headline First Johnnie & Co. Festival in Mumbai
-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Maryland Woman Arrested in Decade-Long Cancer Scam Involving Fake Medical Team
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
Closing a Business with Payroll Taxes Owed - Clear Start Tax Explains the Trust Fund Recovery Penalty
-
Ondas, Palantir and Regna AI Host Key Defense Technology Leaders to Accelerate the Path from AI Innovation to Fielded Capability
-
Dateline appoints Tony Ferguson as Acting Chairman
-
American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
-
AI Search Engineers Says Longer AI Mode Questions Mean Professional Service Firms Should Answer Full Client Questions Directly on Their Pages
-
Arrive AI's Pro Forma Stockholders' Equity Now Above Nasdaq Minimum Requirement Following Recent Transactions
-
Who Does the Best Rhinoplasty in Sarasota?
-
PodcastOne (NASDAQ:PODC) Launches People Pleasers Podcast hosted by Comedians Leah Rudick and Jessica Michelle Singleton
-
Alset AI Closes Non-Brokered Private Placement Offering
-
Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
-
barq Signs MoU with TenPay Global to Enhance Remittances and Digital Payments in China
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
Cytta Air Expands Military Contracting Expertise - Appoints Rear Admiral James "Gib" Godwin III to Advisory Board
-
APEX FTE Expo 2026 Unites Aviation Leaders in Singapore and Honors Passenger Experience Excellence
-
APEX Honors Aeroméxico CEO Dr. Andrés Conesa with Historic APEX CEO Lifetime Achievement Award
-
Enmarket to Open Newest Eatery Location in Rincon, GA
-
Eylsia Nicolas Hits No. 1 on Groover's Global and US Singer-Songwriter Charts with "One More Moment," as Taglish Preview of "Wake Me Up for Christmas" Passes One Million Views in Under 24 Hours
-
What Is the Best Social Media Platform for Peptides?
-
WhalesBot Advances Creativity-Driven AI and Coding Education Through Pubbo AI
-
Karviva Introduces Unwined Alcohol-Free Malbec and Rose Varieties
-
Tidal Wave Auto Spa Opens New Locations in Murfreesboro, Tennessee and Asheville, North Carolina This Week
-
Peoples Bancorp Announces Cash Dividend
-
Jaguar Health, Inc. Announces Reverse Stock Split
-
Kartoon Studios' Beacon Media Partners With Bandai on Tamagotchi's Landmark 30th Anniversary Times Square Celebration
-
First Phosphate and Zeo Energy Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
-
Taylor Bank Announces $125,000 Commitment to Diakonia's Supportive Living Campus Capital Campaign
-
AsiaFIN Holdings Corp. Appoints Fortune Angel INC as U.S. Reseller Partner to Expand Its Agentic and Robotic Process Automation SaaS Business Across New York and the East Coast
-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage.
ORLANDO, FLORIDA / ACCESS Newswire / October 28, 2025 / Exousia Pro, Inc. (formerly Marijuana, Inc.) (OTCPINK:MAJI), a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is pleased to announce it has received Orphan Drug Designation from the FDA, for malignant Glioma, aka Glioblastoma multiforme (GBM).
Exousia Pro's subsidiary, Exousia AI, along with Dr. Marvin S. Hausman, filed for Orphan Drug Designation last year for its exosome-based GBM treatment. The ODD approved by the FDA opens a world of opportunities for advancing the company's cancer therapy as it moves into the next clinical phases.
"GBM is the most common and highly malignant central nervous system (CNS) tumor that currently lacks adequate treatment," stated Marvin S. Hausman, MD, Chairman of the Scientific Advisory Board (SAB). "Our breakthrough exosomal technology has the ability to deliver a wide range of therapeutics, including genetic material, into cells afflicted with cancer, such as GBM. The therapeutic technology presented in this orphan drug application is a method for using exosomes loaded with desired nucleic acids, in the effective treatment of GBM when combined with currently available standard anticancer therapy."
To receive Orphan Drug Designation, a company, like Exousia AI, must submit a request to the FDA with a scientific rationale demonstrating a medically plausible basis for expecting the drug to be effective in treating the rare disease. Preclinical or clinical data often support this rationale. The FDA reviews these requests and, if the criteria are met, grants the orphan drug designation.
"The Company is very excited to have been granted this designation," stated Matthew Dwyer, President of Exousia Pro. "It is hard for us to quantify the value of ODD as it is likely in the 10's of millions of dollars. We will soon begin working with investment bankers to monetize the ODD as we advance our therapy. GBM is a terrible disease and pretty much a death sentence for most. We believe our combination therapy has the potential to be disease-modifying and could make a huge difference for this patient population."
About Exousia Pro, Inc.
Exousia Pro, Inc. (EXO), a leader in exosome-based biotechnology, develops and manufactures mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. EXO's breakthrough platform enables the custom production of exosomes with enhanced genetic functionality, capable of selectively targeting specific cells to address diseases with significant unmet medical needs. These engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including Glioblastoma and Pancreatic cancer, thereby improving patient responsiveness to anticancer therapies. The same platform technology also holds promise for treating a broad spectrum of viral infections.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
[email protected]
SOURCE: Exousia Pro, Inc.
View the original press release on ACCESS Newswire
J.Gomez--AT